((Z)-1-Methoxy-pent-1-enyloxy)-trimethyl-silane | 84393-10-2

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机类金属化合物
• 英文名称: ((Z)-1-Methoxy-pent-1-enyloxy)-trimethyl-silane
• 英文别名: [(1-Methoxypent-1-en-1-yl)oxy](trimethyl)silane；1-methoxypent-1-enoxy(trimethyl)silane
• CAS: 84393-10-2
• 化学式: C₉H₂₀O₂Si
• 分子量: 188.342
• InChiKey: LMEUBJDLHAHRIF-UHFFFAOYSA-N

物化性质

• 沸点：
  180.7±23.0 °C(Predicted)
• 密度：
  0.860±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.13
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ((Z)-1-Methoxy-pent-1-enyloxy)-trimethyl-silane 在 zinc(II) chloride 作用下， 以 二氯甲烷 为溶剂， 生成 3-Methoxy-2,4-dipropyl-pentanedioic acid dimethyl ester
  参考文献：
  名称：

  A Convenient Synthesis of Dialkyl Esters of 3-Methoxy-2,4-dialkylpentanedioic Acids

  摘要：

  DOI：

  10.1055/s-1982-29913

文献信息

• A New Magnesium-Catalyzed Doubly Diastereoselective <i>anti</i>-Aldol Reaction Leads to a Highly Efficient Process for the Total Synthesis of Lactacystin in Quantity
  作者：E. J. Corey、Weidong Li、Gregory A. Reichard

  DOI：10.1021/ja973444c

  日期：1998.3.1

  is described for metal-catalyzed doubly diastereoselective Mukaiyama aldol coupling of a chiral tertiary α-amino aldehyde and an achiral silyl enol ether to form selectively an anti-aldol product. The metal requirement is strict, since of several salts tested only MgI2 functions as an effective catalyst. The MgI2-catalyzed aldol greatly facilitates the total synthesis of lactacystin (1) and the corresponding

  描述了一种用于金属催化双非对映选择性 Mukaiyama 羟醛偶联手性叔 α-氨基醛和非手性甲硅烷基烯醇醚以选择性形成抗羟醛产物的新方法。金属要求很严格，因为在测试的几种盐中，只有 MgI2 作为有效催化剂起作用。MgI2 催化的羟醛极大地促进了乳胞素 (1) 和相应的 β-内酯 (2) 的全合成，这些微生物产物是蛋白酶体功能、细胞周期进程和基因调控的有效和选择性抑制剂。该方法还允许合成 1 的类似物，其中乳胱氨酸的 7β-甲基被高级烷基或芳烷基取代。
• Connective synthesis of 5,5-disubstituted hydantoins by tandem α-amination and α-arylation of silyl ketene acetals
  作者：Rakesh K. Saunthwal、Matthew T. Cornall、Roman Abrams、John W. Ward、Jonathan Clayden

  DOI：10.1039/c8sc05263h

  日期：——

  5-Disubstituted hydantoins, formally the cyclisation products of quaternary amino acids, were formed connectively from simple ester-derived starting materials by a one-pot tandem method. Amination of the silyl ketene acetal derivative of a methyl ester takes place by silver-catalysed addition to the NN bond of an azocarboxamide, generating a N-amino-N′-aryl urea derivative of a substituted aminoester. Treatment

  5,5-二取代乙内酰脲，形式上是季氨基酸的环化产物，是通过一锅串联法由简单的酯衍生原料连接形成的。甲基酯的甲硅烷基乙烯酮缩醛衍生物的胺化通过银催化加成到偶氮甲酰胺的 N N 键，产生N-氨基-N取代氨基酯的'-芳基脲衍生物。用碱处理形成酯烯醇化物，其通过芳基环的分子内迁移到酯的α-位而发生芳基化。产品经过环闭合形成乙内酰脲，其本身可能被去保护和功能化。芳基迁移对于具有各种电子特性的环以及带有官能化和非官能化链的酯是成功的，并且产品具有与几种生物活性化合物的共同特征。
• Pd/Josiphos-Catalyzed Enantioselective α-Arylation of Silyl Ketene Acetals and Mechanistic Studies on Transmetalation and Enantioselection
  作者：Kenya Kobayashi、Yasunori Yamamoto、Norio Miyaura

  DOI：10.1021/om200945q

  日期：2011.11.28

  5-MePh)2PF-Pcy2) catalyzed the enantioselective arylation of silyl ketene acetals with iodoarenes in the presence of TlOAc to promote transmetalation of silyl ketene acetals. The highest enantioselectivities giving α-arylesters up to 91% ee were achieved when (E)-1-methoxy-1-(trimethylsiloxy)propene (E/Z = 88/12) was used for the silyl ketene acetal. The effect on enantioselection of a chiral ligand is discussed

  在TlOAc存在下，钯/（4-MeO-3,5-MePh）2 PF-Pcy 2）催化硅烷基乙烯酮缩醛与碘芳烃的对映选择性芳基化，以促进硅烷基乙烯酮缩醛的金属转移。当将（E）-1-甲氧基-1-（三甲基甲硅烷氧基）丙烯（E / Z = 88/12）用于甲硅烷基烯酮缩醛时，可获得最高91％ee的α-芳基酯的最高对映选择性。基于钯/（4-MeO-3,5-MePh）2 PF-Pcy 2）配合物的X射线结构以及DFT在机械方面的计算研究结果，讨论了对手性配体对映体选择的影响催化循环。
• MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-kB ACTIVITY AND USE THEREOF
  申请人：Sheppeck James E.

  公开号：US20100075961A1

  公开（公告）日：2010-03-25

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically acceptable salt, or hydrate, thereof, wherein X is (Ia); or X is (Ib); or X is (Ic); (Id) is heterocycle or heteroaryl; E is —N—, —NR 1 —, —O—, —S—, —SO 2 — or —CR 2 —; F is —N—, —NR 1a —, —O—, —S—, —SO 2 — or —CR 2a —; G is N, —NR 1b —, —O—, —S—, —SO 2 — or —CR 2b —, provided that the E-F-G containing heterocyclic ring formed does not contain a S—S or S—O bond, and at least one of E, F and G is a heteroatom; J, J a , M, M a , Q, R x , R y , R 1 , R 1a , R 1b , R 2 , R 2a , R 2b , and R 3 to R 21 , Z, Z a , Z b , and Z c are as defined above.

  提供了一种新型的非类固醇化合物，其结构式（I）及其对映异构体、二对映异构体或其药学上可接受的盐或水合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括炎症和免疫性疾病、肥胖和糖尿病，其中X为（Ia）; 或X为（Ib）; 或X为（Ic）; （Id）为杂环或杂芳基; E为—N—、—NR1—、—O—、—S—、—SO2—或—CR2—; F为—N—、—NR1a—、—O—、—S—、—SO2—或—CR2a—; G为N、—NR1b—、—O—、—S—、—SO2—或—CR2b—，但E、F和G中含有的杂环环不含有S—S或S—O键，且E、F和G中至少有一个是杂原子; J、Ja、M、Ma、Q、Rx、Ry、R1、R1a、R1b、R2、R2a、R2b和R3到R21、Z、Za、Zb和Zc的定义如上所述。
• Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
  申请人：Bristol-Myers Squibb Company

  公开号：US08198311B2

  公开（公告）日：2012-06-12

  Novel non-steroidal compounds are provided which are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including inflammatory and immune diseases, obesity and diabetes having the structure of formula (I), its enantiomers, diastereomers, or a pharmaceutically acceptable salt, or hydrate, thereof, wherein X is (Ia); or X is (Ib); or X is (Ic); (Id) is heterocycle or heteroaryl; E is —N—, —NR1—, —O—, —S—, —SO2— or —CR2—; F is —N—, —NR1a—, —O—, —S—, —SO2— or —CR2a—; G is N, —NR1b—, —O—, —S—, —SO2— or —CR2b—, provided that the E-F-G containing heterocyclic ring formed does not contain a S—S or S—O bond, and at least one of E, F and G is a heteroatom; J, Ja, M, Ma, Q, Rx, Ry, R1, R1a, R1b, R2, R2a, R2b, and R3 to R21, Z, Za, Zb, and Zc are as defined above.

  提供了一种新型的非甾体化合物，其结构式为（I），其对调节糖皮质激素受体、AP-1和/或NF-κB活性相关的疾病，包括炎症和免疫性疾病、肥胖症和糖尿病具有治疗作用，其中X为（Ia）；或X为（Ib）；或X为（Ic）；（Id）为杂环或杂环芳基；E为—N—、—NR1—、—O—、—S—、—SO2—或—CR2—；F为—N—、—NR1a—、—O—、—S—、—SO2—或—CR2a—；G为N、—NR1b—、—O—、—S—、—SO2—或—CR2b—，其中E、F和G中至少一个为杂原子，但E-F-G所含的杂环不含S—S或S—O键；J、Ja、M、Ma、Q、Rx、Ry、R1、R1a、R1b、R2、R2a、R2b和R3至R21、Z、Za、Zb和Zc的定义如上。其中所述化合物可以是其对映体、非对映异构体、药学上可接受的盐或水合物。